London-listed AstraZeneca said on Monday it would make an upfront payment of $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a newer class of treatments called antibody drug conjugates (ADC).from Moneycontrol Business News https://ift.tt/2WVnZVm
Comments
Post a Comment